These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 20466145

  • 1. The binding of vinca domain agents to tubulin: structural and biochemical studies.
    Cormier A, Knossow M, Wang C, Gigant B.
    Methods Cell Biol; 2010; 95():373-90. PubMed ID: 20466145
    [Abstract] [Full Text] [Related]

  • 2. Structural plasticity of tubulin assembly probed by vinca-domain ligands.
    Ranaivoson FM, Gigant B, Berritt S, Joullié M, Knossow M.
    Acta Crystallogr D Biol Crystallogr; 2012 Aug; 68(Pt 8):927-34. PubMed ID: 22868758
    [Abstract] [Full Text] [Related]

  • 3. Structural basis for the regulation of tubulin by vinblastine.
    Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, Sobel A, Knossow M.
    Nature; 2005 May 26; 435(7041):519-22. PubMed ID: 15917812
    [Abstract] [Full Text] [Related]

  • 4. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
    Lobert S, Vulevic B, Correia JJ.
    Biochemistry; 1996 May 28; 35(21):6806-14. PubMed ID: 8639632
    [Abstract] [Full Text] [Related]

  • 5. Fluorescence spectroscopic methods to analyze drug-tubulin interactions.
    Bhattacharyya B, Kapoor S, Panda D.
    Methods Cell Biol; 2010 May 28; 95():301-29. PubMed ID: 20466142
    [Abstract] [Full Text] [Related]

  • 6. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain.
    Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M.
    Nature; 2004 Mar 11; 428(6979):198-202. PubMed ID: 15014504
    [Abstract] [Full Text] [Related]

  • 7. Insight into the GTPase activity of tubulin from complexes with stathmin-like domains.
    Wang C, Cormier A, Gigant B, Knossow M.
    Biochemistry; 2007 Sep 18; 46(37):10595-602. PubMed ID: 17711308
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
    Kelly EB, Tuszynski JA, Klobukowski M.
    J Mol Graph Model; 2011 Sep 18; 30():54-66. PubMed ID: 21798777
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic selectivity of vinca alkaloids: a role for guanosine 5'-triphosphate?
    Houghton PJ, Houghton JA, Bowman LC, Hazelton BJ.
    Anticancer Drug Des; 1987 Oct 18; 2(2):165-79. PubMed ID: 3329524
    [Abstract] [Full Text] [Related]

  • 11. Linkages in tubulin-colchicine functions: the role of the ring C (C') oxygens and ring B in the controls.
    Pérez-Ramírez B, Gorbunoff MJ, Timasheff SN.
    Biochemistry; 1998 Feb 10; 37(6):1646-61. PubMed ID: 9484236
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and biological evaluation of vinca alkaloids and phomopsin hybrids.
    Ngo QA, Roussi F, Cormier A, Thoret S, Knossow M, Guénard D, Guéritte F.
    J Med Chem; 2009 Jan 08; 52(1):134-42. PubMed ID: 19072542
    [Abstract] [Full Text] [Related]

  • 13. Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids.
    Coderch C, Morreale A, Gago F.
    Anticancer Agents Med Chem; 2012 Mar 08; 12(3):219-25. PubMed ID: 22044006
    [Abstract] [Full Text] [Related]

  • 14. Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents.
    Sackett DL.
    Biochemistry; 1995 May 30; 34(21):7010-9. PubMed ID: 7766610
    [Abstract] [Full Text] [Related]

  • 15. Structure-based identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin.
    Ravi M, Zask A, Rush TS.
    Biochemistry; 2005 Dec 06; 44(48):15871-9. PubMed ID: 16313189
    [Abstract] [Full Text] [Related]

  • 16. N-terminal stathmin-like peptides bind tubulin and impede microtubule assembly.
    Clément MJ, Jourdain I, Lachkar S, Savarin P, Gigant B, Knossow M, Toma F, Sobel A, Curmi PA.
    Biochemistry; 2005 Nov 08; 44(44):14616-25. PubMed ID: 16262261
    [Abstract] [Full Text] [Related]

  • 17. Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers.
    Barbier P, Dorléans A, Devred F, Sanz L, Allegro D, Alfonso C, Knossow M, Peyrot V, Andreu JM.
    J Biol Chem; 2010 Oct 08; 285(41):31672-81. PubMed ID: 20675373
    [Abstract] [Full Text] [Related]

  • 18. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
    Bai RL, Pettit GR, Hamel E.
    J Biol Chem; 1990 Oct 05; 265(28):17141-9. PubMed ID: 2211617
    [Abstract] [Full Text] [Related]

  • 19. Theoretical insight into the structural mechanism for the binding of vinblastine with tubulin.
    Chi S, Xie W, Zhang J, Xu S.
    J Biomol Struct Dyn; 2015 Oct 05; 33(10):2234-54. PubMed ID: 25588192
    [Abstract] [Full Text] [Related]

  • 20. Characterization of the interaction of cryptophycin 1 with tubulin: binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction.
    Bai R, Schwartz RE, Kepler JA, Pettit GR, Hamel E.
    Cancer Res; 1996 Oct 01; 56(19):4398-406. PubMed ID: 8813133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.